The purpose of this FOA is to provide investigators with a mechanism to access contract research/medical organizations (CROs/CMOs) and subject matter experts (SMEs) within the NINDS Ultra-Rare Gene-based Therapy (URGenT) Network to support planning, manufacturing, and limited nonclinical therapeutic development efforts.
Companion FOA: PAR-22-030 , U01 Research Project (Cooperative Agreements)
Deadlines:
Application Due Dates:
December 22, 2021 - January 31, 2022
February 1, 2022 - May 31, 2022
June 1, 2022 - September 30, 2022
October 1, 2022 - January 31, 2023
February 1, 2023 - May 31, 2023
June 1, 2023 - September 30, 2023
October 1, 2023 - January 31, 2024
February 1, 2024- May 31, 2024
June 1, 2024 - September 30, 2024
October 1, 2024-January 24, 2025
PAR-22-028 Expiration Date New Date January 25, 2025 (Original Date: October 01, 2024) per issuance of NOT-NS-24-035
Sponsor Institute/Organizations: National Institutes of Health
Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA
Sep 30, 2024
Varies
Affiliation: National Institutes of Health
Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.